CureLab Veterinary, Inc.

Elenavet® is poised to revolutionize cancer treatment in dogs and cats!

Claim My Business
Security Type
Pets/Animals, Healthcare & Medical, Life Sciences
Min Investment
Dedham, MA
Expected Close Date
May 19, 2023
Target Raise
Security Price
Number of Employees
Short Term Debt
Cost of Goods
Long Term Debt
Net Income

Key Deal Facts

Using our product line, veterinarians successfully treated 10 out of 11 dogs with breast cancer.
Large Market: The US market is actively growing with pet ownership approaching 67% of households.
175 million dogs in the USA and Europe and the number is growing. 1 in 4 will develop cancer.
199 million cats in US, and Europe and the number is growing. 1 in 5 cats will develop cancer.
Elenavet also has strong potential for treating osteoarthritis, IBD, and other inflammatory mediated diseases.
80% of dogs over 7 and 90% of cats over 12 develop osteoarthritis.
Exclusive licensure of strong intellectual Property & Patents in over 20 countries.
Pet ownership provides the owner with many health benefits Elenavet hopes to help them live longer.

Management Team / Advisory Board Bios

Alexander Shneider Chairman of the Board, FounderOver 25 years of biotech and entrepreneurial experience. Achievements and activities include drug development from concept to market authorization, patents in all major jurisdictions, and advisory role for successful exits., Robert E Devlin PresidentExperience as both a practicing veterinarian and as successful veterinary business executive. Extensive knowledge of US animal health market across sales channels and internationally as well., Jason Payne CFOComprehensive experience including planning and directing execution of day-to-day accounting and long term financial management initiatives. Experience in both public and private companies and growing a new business unit from $0 to $140MM., Stephen Spector VP of Strategic BDSteve past experience includes online B2B & B2C marketing & sales of Techmira Corp., marketing patented teeth-cleaning products for pets and pain-reducing anti-inflammatory devices.
Amount Raised : $100,201
Reveal the Score by Voting
Additional ratings from other users are needed to determine a viable CrowdScore for this deal.
The "CrowdScore" for this deal is determined by user ratings and other factors using our proprietary algorithm.
The overall viability and scalability of the business concept as well as the ability to drive the concept to profitability over time.
Business Idea
The progress made thus far in demonstrating that the business has viability, a customer base or other business traction.
Business Traction
The experience of the management team in running, scaling and/or exiting a business that required similar skills to execute the business plan.
Management Team
The value of the company compared to similar companies raising money from investors.

Security Description

A CAFES (Contract and Future Equity Stake) can convert into different types of equity upon a Triggering Event, such as: common or preferred stock for a corporation, limited partnership interest for a limited partnership and membership interest for a limited liability company. At the time of the Triggering Event, the specific rights and limitations associated with the equity stake being issued to the investors will be determined and disclosed by the Entrepreneur.

Research Reports

No reports have been submitted

Become a Reporter